Authors: Sharif, Najam A; Klimko, Peter

Source: Expert Review of Ophthalmology, Volume 4, Number 5, October 2009 , pp. 477-489(13)

Publisher: Expert Reviews

Abstract:

The discovery of potent and efficacious intraocular pressure (IOP)-lowering FP-class prostaglandin (PG) analogs has revolutionized the treatment of ocular hypertension, a major risk factor for progression of the blinding disease glaucoma. Three isopropyl ester pro-drugs (i.e., latanoprost, travoprost and unoprostone) and one amide pro-drug (bimatoprost) of w-chain-modified analogs of PGF_2α are approved for lowering IOP and treating glaucoma. It is believed that these pro-drugs are sufficiently lipophilic to readily penetrate the cornea/conjunctiva upon topical ocular dosing whereupon they are hydrolyzed with liberation of their respective free acid into the aqueous humor. The free acids of these PGs activate the FP receptors in the ciliary muscle (CM) and trabecular meshwork (TM) and cause the release of matrix metalloproteinases that digest the extracellular matrix. This remodeling within the CM and TM creates new and/or enlarges fluid flow pathways, both uveoscleral and conventional, for aqueous humor efflux, which then leads to lowering of the IOP. While it is generally believed that bimatoprost is a pro-drug and that bimatoprost free acid is the active moiety involved in lowering IOP, some have proposed that bimatoprost exerts its actions via a putative `prostamide receptor'. We provide an update on this topic and discuss published data that addresses the debate in this arena.

Keywords: 17-phenyl PGF2α; bimatoprost; FP receptor; glaucoma; ocular hypertension; prostaglandin; prostamide receptor

Document Type: Research article

DOI: http://dx.doi.org/10.1586/eop.09.40

Affiliations: 1: Director, Core Pharmacology and Imaging, Pharmaceutical Products Research, Alcon Research, Ltd (R6-19), 6201 South Freeway, Fort Worth, TX 76134, USA., Email: naj.sharif@alconlabs.com

Publication date: 2009-10-01

More about this publication?

• Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• By this author: Sharif, Najam A ;  Klimko, Peter

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers